| Literature DB >> 23092556 |
Xuesong Chen1, Qingwei Meng, Yanbin Zhao, Meiyan Liu, Dandan Li, Yanmei Yang, Lichun Sun, Guangjie Sui, Li Cai, Xiaoqun Dong.
Abstract
Angiotensin II type 1 receptor (AT1R) promotes tumor invasion, migration, metastasis and angiogenesis. We explored the potential antitumor effects of AT1R antagonists in breast cancer. We found that angiotensin II promoted cell proliferation and upregulated the expression of vascular endothelial growth factor A (VEGF-A) in MCF-7 cells. Losartan downregulated the expression of VEGF-A in MCF-7 cells treated with angiotensin II. Candesartan downregulated the expression of VEGF-A in mice bearing MCF-7 xenografts and inhibited tumor growth and angiogenesis. AT1R and VEGF-A expression correlated with increased microvascular density in 102 breast cancer patients. Our data suggest that AT1R antagonists might be useful to suppress breast cancer by inhibiting the angiotensin II.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23092556 DOI： 10.1016/j.canlet.2012.10.006
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679